Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Caroline Dutriaux"'
Autor:
Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 13
Dummer, R, Long, G V, Robert, C, Tawbi, H A, Flaherty, K T, Ascierto, P A, Nathan, P D, Rutkowski, P, Leonov, O, Dutriaux, C, Mandalà, M, Lorigan, P, Ferrucci, P F, Grob, J J, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, A, Brase, J C, Green, S, Haas, T, Masood, A, Gasal, E, Ribas, A & Schadendorf, D 2022, ' Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.21.01601
Dummer, R, Long, G V, Robert, C, Tawbi, H A, Flaherty, K T, Ascierto, P A, Nathan, P D, Rutkowski, P, Leonov, O, Dutriaux, C, Mandalà, M, Lorigan, P, Ferrucci, P F, Grob, J J, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, A, Brase, J C, Green, S, Haas, T, Masood, A, Gasal, E, Ribas, A & Schadendorf, D 2022, ' Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.21.01601
PURPOSEPreclinical data suggest the combination of an anti–programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::512e67c5f66bacf61087d7e838e0dc59
https://www.zora.uzh.ch/id/eprint/213526/
https://www.zora.uzh.ch/id/eprint/213526/
Autor:
Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
International audience; Background: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM). In a la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2
https://hal.science/hal-03401780
https://hal.science/hal-03401780
Autor:
Florent Martin, Amaury Daste, Marie Beylot-Barry, Marie-Elise Truchetet, Julie Lallier, Sorilla Prey, Caroline Dutriaux, Edouard Forcade, Marine Gross-Goupil, Alain Ravaud, Bernard Bannwarth, Christophe Richez, Thierry Schaeverbeke, Nadia Mehsen, Thomas Barnetche, Léa Rouxel, Léa Dousset, R. Veillon, Marie Kostine, Anne Pham-Ledard
Publikováno v:
Annals of the Rheumatic Diseases. 77:393-398
ObjectivesTo evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response.MethodsThis was a single-centre prospective ob
Autor:
Helen Gogas, Victor Sandor, Naoya Yamazaki, Reinhard Dummer, Keith T. Flaherty, Gabriella Liszkay, Laure A. De Parseval, Caroline Dutriaux, Paolo A. Ascierto, Michael D Pickard, Ivana Krajsová, Mario Mandalà, Vanna Chiarion-Sileni, Ralf Gutzmer, Claus Garbe, Ana Arance, Caroline Robert, Jan Willem de Groot, Dirk Schadendorf, Carmen Loquai
9504Background: Combined BRAF/MEK inhibitor therapy is standard of care in advanced BRAFV600-mutant melanoma. COLUMBUS Part 1 evaluated ENCO 450 mg once daily (QD) + BINI 45 mg twice daily (BID;COM...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1291a0651d1a21b1418b474ac1ea609a
Autor:
Alain Duhamel, Caroline Dutriaux, Xavier Mirabel, Emilie Le Rhun, Caroline Robert, Jean-Philippe Lacour, Céleste Lebbé, C. Templier, E. Desmedt, Luc Thomas, Nicolas Reyns, Philippe Jamme, Jean-Jacques Grob, Laurent Mortier, Philippe Saiag, Laurent Machet, Thierry Lesimple
Publikováno v:
Journal of Clinical Oncology. 36:9520-9520
9520Background: Brain metastasis commonly occur in patients with metastatic melanoma (MM) and are managed with surgery or stereotactic radiosurgery (SRS) and/or systemic treatment based on BRAF sta...
Autor:
Marie Beylot-Barry, Laurent Mortier, Sophie Dalac, Florence Brunet-Possenti, Marie Thérèse Leccia, O. Becquart, Pierre-Emmanuel Stoebner, Catherine Lok, François Aubin, Caroline Dutriaux, Bernard Guillot, Philippe Saiag, Stéphane Dalle, Thierry Lesimple, Brigitte Dréno, Julie De Quatrebarbes, Jean-Philippe Lacour, Bastien Oriano, Raphaël Porcher, Céleste Lebbé
Publikováno v:
Journal of Clinical Oncology. 36:e21536-e21536
e21536Background: Melanoma’s incidence is increasing, and elderly people could be significantly impacted since more than 50% of melanoma arise in > 65 years-old (yo). Combined BRAF and MEK targeted...
Autor:
Axel Hauschild, John M. Kirkwood, Paola Aimone, Caroline Robert, Mario Mandalà, Laurent Mortier, Bijoyesh Mookerjee, Ran Ji, Dirk Schadendorf, Andrew Haydon, Mario Santinami, Reinhard Dummer, Caroline Dutriaux, James Larkin, Richard F. Kefford, Georgina V. Long, Victoria Atkinson, Jacob Schachter, Vanna Chiarion-Sileni, Marta Nyakas
Publikováno v:
Journal of Clinical Oncology. 36:9591-9591
9591Background: The COMBI-AD trial demonstrated that adjuvant treatment with D + T in patients (pts) with resected stage III BRAF-mutant melanoma significantly reduced the risk of melanoma recurren...
Autor:
Naoya Yamazaki, Carmen Loquai, Keith T. Flaherty, Vanna Chiarion-Sileni, Ivana Krajsová, Jan Willem de Groot, Dirk Schadendorf, Ana Arance, Caroline Dutriaux, Helen Gogas, Mario Mandalà, Laure A. De Parseval, Gabriella Liszkay, Michael D Pickard, Ashwin Gollerkeri, Caroline Robert, Ralf Gutzmer, Claus Garbe, Reinhard Dummer, Paolo A. Ascierto
Publikováno v:
Journal of Clinical Oncology. 36:9567-9567
9567Background: Combination BRAF/MEK inhibitor (BRAFi/MEKi) therapy is standard of care for BRAFV600-mutant metastatic melanoma. In COLUMBUS Part 1, encorafenib 450 mg once daily (QD) + binimetinib...
Autor:
Sandrine Monestier, Nicole Basset-Seguin, Jeannie Hou, N. Poulalhon, Laurent Mortier, Martine Bagot, Caroline Dutriaux, Caroline Robert, Fred de Sauvage, Nicolas Meyer, Brigitte Dréno, Bernard Guillot, Philippe Saiag, Amir Khammari, Hayley J. Sharpe, Florent Grange
Publikováno v:
Journal of Clinical Oncology. 34:9562-9562
9562Background: A Hh pathway inhibitor, vismodegib (VISMO) is approved for the treatment of locally advanced (la BCC) and metastatic BCC (mBCC). While most patients respond to drug treatment, in th...
Autor:
Piotr Rutkowski, Luc Thomas, Mario Mandalà, James Ford, Marine Weill, Ralf Gutzmer, Caroline Dutriaux, Ana Maria Arance Fernandez, Keith T. Flaherty, Michele Maio, Michele Del Vecchio, Ernesto Wasserman, Viviana Bozon, Reinhard Dummer, Paolo A. Ascierto, Dirk Schadendorf, L. Andres Sirulnik, Georgina V. Long, Valentine Jehl
Publikováno v:
Journal of Clinical Oncology. 34:9500-9500
9500Background: NRAS mutation in melanoma occurs in ~20% of patients (pts). There are no specific therapies for NRAS melanoma. Despite emergence of immunotherapies (ITs) as effective treatments in ...